Liver Related Research

The goal of my research is to use all-human structured biomimetic liver microphysiology systems (MPS) to model both normal and disease-state liver physiology. My main interests are in coupling the use of quantitative systems pharmacology (QSP) and biomimetic liver MPS as a precision medicine platform to provide new mechanistic detail and predict and/or initiate the development of novel therapeutics for MASLD/MASH as well as help to optimize patient cohort selection for clinical trials and to identify novel biomarkers and targets for drug discovery. In addition, I am interested in using liver MPS to examine the impact of the liver tumor microenvironment on metastatic phenotypes that are associated with the progression of different cancer types (metastatic melanoma and breast cancer). 

Collaborations:

(1) Lans Taylor MASLD drug testing using quantitative systems pharmacology and liver MPS; Modeling the liver metastatic niche for melanoma using liver MPS)

(2) Alex Soto-Gutierrez and Jai Behari (MASLD/MASH NCATS clinical trials on a chip program)

I can provide collaboration or training for use of liver MPS platforms for normal and disease state physiology studies. 

View Dr. Miedel’s publications on Pubmed

View Dr. Miedel’s NIH funding on Reporter.